Table 1. Comparison of patient characteristics according to the anticancer effect.
| Variable | Responder (PR+SD) ( n =18) | Non-responder (PD) ( n =17) | P -value |
|---|---|---|---|
| Age – years | 70.5 (54–78) | 74 (35–80) | 0.95 |
| Sex – no. (%) | 1 | ||
| Male | 13 (72) | 12 (71) | |
| Female | 5 (28) | 5 (29) | |
| Cause of disease – no. (%) | 0.82 | ||
| Hepatitis B | 3 (17) | 4 (24) | |
| Hepatitis C | 9 (50) | 9 (53) | |
| Non-B, non-C | 6 (33) | 4 (24) | |
| ECOG performance status – no. (%) | 0.49 | ||
| 0 | 18 (100) | 16 (94) | |
| 1 | 0 (0) | 1 (6) | |
| BCLC stage – no. (%) | 0.51 | ||
| B (intermediate) | 11 (61) | 8 (47) | |
| C (advanced) | 7 (39) | 9 (53) | |
| Tumour grade – no. (%) | 0.62 | ||
| Well | 2 (11) | 0 (0) | |
| Moderate | 11 (61) | 12 (71) | |
| Poor | 5 (28) | 5 (29) | |
| AFP (ng ml−1) – median (range) | 276 (2–22 619) | 89 (3–228 540) | 0.56 |
| DCP (mAU ml−1) – median (range) | 641 (5–26 624) | 481.5 (9–61 180) | 0.93 |
| Previous therapy (last) – no. (%) | 0.09 | ||
| OP | 1 (6) | 5 (29) | |
| RFA | 1 (6) | 2 (12) | |
| TACE | 11 (61) | 10 (59) | |
| HAIC | 3 (17) | 0 (0) | |
| None | 2 (11) | 0 (0) |
Abbreviations: ECOG=Eastern Cooperative Oncology Group; BCLC=Barcelona Clinic Liver Cancer; AFP=α-fetoprotein; DCP=des-γ-carboxyprothrombin; OP=operation; RFA=radiofrequency ablation; TACE=transcatheter arterial chemoembolization; HAIC=hepatic arterial chemotherapy using implanted port system; PR=partial response; SD=stable disease; PD=progressive disease.